Drug development for movement disorders like Parkinson’s disease (PD) and Huntington's disease (HD) has been challenging. Continuous, objective data from digital health technologies (DHTs) can address gaps in current measures by providing critical information needed to enhance study design and detect treatment
Schedule a Meeting Download the Guide
To learn more about opportunities with wearable digital health technologies in Parkinson’s disease clinical trials, download our full guide.
Download the Guide
Listen to experts from Neuron23, PKG Health, and Ametris discuss the unique challenges of PD R&D, share the current state-of-the-art DHT solutions and outline how digital measures can help advance treatments for this group of patients.
Digital health technologies can more accurately assess daily patient function in PD and HD clinical trials, increasing the sensitivity of outcome measures. Through Ametris' partnership with Indivi, researchers can also collect active digital measures of motor and non-motor symptoms more frequently for a comprehensive view of patients’ capacity, perception, and performance.
Watch our recent webinar with Indivi to learn more details about the opportunity to collect more sensitive assessments in movement disorder research and drug development with active and passive DHT monitoring.
